Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS).

[1]  W. Kannel,et al.  Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.

[2]  P. Hjemdahl,et al.  Psychosocial variables in female vs male patients with stable angina pectoris and matched healthy controls. , 1997, European heart journal.

[3]  C. Held,et al.  Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study In Stockholm (APSIS). A comparison with healthy controls , 1997, Journal of internal medicine.

[4]  G. Dagenais,et al.  Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. , 1996, Circulation.

[5]  C. Held,et al.  Prognosis of patients with stable angina pectoris on antianginal drug therapy. , 1996, The American journal of cardiology.

[6]  C. Held,et al.  Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) , 1996, European heart journal.

[7]  David Machin,et al.  Survival Analysis: A Practical Approach , 1995 .

[8]  S. Yusuf,et al.  Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? , 1995, Circulation.

[9]  G. Assmann,et al.  Dose-Response Relationships of Serum Lipid Measurements With the Extent of Coronary Stenosis , 1995 .

[10]  H. Lithell.  Metabolic aspects of the treatment of hypertension , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[11]  A. Garfagnini,et al.  Relationship between HDL-cholesterol and apolipoprotein A1 and the severity of coronary artery disease. , 1995, European heart journal.

[12]  K. Bailey,et al.  The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[13]  J. Patsch,et al.  Triglyceride-rich lipoproteins and atherosclerosis. , 1994, Atherosclerosis.

[14]  G. Bondjers.  Anti-atherosclerotic effects of beta-blockers. , 1994, European heart journal.

[15]  N. Wald,et al.  Apolipoproteins and ischaemic heart disease: implications for screening , 1994, The Lancet.

[16]  G. Assmann,et al.  Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. , 1992, The American journal of cardiology.

[17]  G. Thorgeirsson,et al.  Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. , 1992, The American journal of cardiology.

[18]  K. Anderson,et al.  Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. , 1992, Journal of the American College of Cardiology.

[19]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[20]  P. Durrington,et al.  Clinical Value of Apolipoprotein Measurement , 1991, Annals of clinical biochemistry.

[21]  W. Willett,et al.  A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. , 1991, The New England journal of medicine.

[22]  C. Furberg,et al.  Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. , 1991, The American journal of cardiology.

[23]  N. Kaplan.  Cardiovascular risk reduction: the role of antihypertensive treatment. , 1991, The American journal of medicine.

[24]  D. McTavish,et al.  Verapamil , 2012, Drugs.

[25]  N. Al-Muhtaseb,et al.  Research paperLipoproteins and apolipoproteins in young male survivors of myocardial infarction , 1989 .

[26]  M. Austin.  Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. , 1989, American journal of epidemiology.

[27]  L. Hunt,et al.  APOLIPOPROTEINS (a), AI, AND B AND PARENTAL HISTORY IN MEN WITH EARLY ONSET ISCHAEMIC HEART DISEASE , 1988, The Lancet.

[28]  S. Manuck,et al.  The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. , 1987, European heart journal.

[29]  D. Gordon,et al.  High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. , 1986, Circulation.

[30]  L. Kuller,et al.  Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial. , 1986, The American journal of cardiology.

[31]  N. Al-Muhtaseb,et al.  Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction , 1986 .

[32]  W. Kannel.  Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. , 1985, American heart journal.

[33]  P. D. Henry.  Atherosclerosis, calcium, and calcium antagonists. , 1985, Circulation.

[34]  J. Salonen,et al.  Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. , 1985, The American journal of cardiology.

[35]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[36]  W. Kannel,et al.  Lipoproteins, cardiovascular disease, and death. The Framingham study. , 1981, Archives of internal medicine.

[37]  L Wilhelmsen,et al.  Multivariate Analyses of Serum Apolipoproteins and Risk Factors in Relation to Acute Myocardial Infarction , 1981, Arteriosclerosis.

[38]  G. Cazzolato,et al.  ARE APOLIPOPROTEINS BETTER DISCRIMINATORS THAN LIPIDS FOR ATHEROSCLEROSIS? , 1979, The Lancet.

[39]  D. Thelle,et al.  The Tromsø Heart Study: Serum apolipoprotein Al concentration in relation to future coronary heart disease , 1978, European journal of clinical investigation.

[40]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[41]  M. Lopes-Virella,et al.  Cholesterol determination in high-density lipoproteins separated by three different methods. , 1977, Clinical chemistry.

[42]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[43]  Ramsay Dh,et al.  Markingink poisoning: an outbreak of methaemoglobin cyanosis in newborn babies. , 1959, Lancet.

[44]  Statens Beredning för Utvärdering av Medicinsk Metodik.  Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care. , 1995, Journal of internal medicine. Supplement.

[45]  M. Austin.  Plasma triglyceride and coronary heart disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[46]  Nie Fe.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II) , 1990 .

[47]  Rupert G. Miller,et al.  Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.